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alectin-1 is a component of the extracellular ma-
trix as well as a ligand of cell surface counter
receptors such as 
 
 
 
-galactoside–containing gly-
colipids, however, the molecular mechanism of galectin-1
secretion has remained elusive. Based on a nonbiased
screen for galectin-1 export mutants we have identiﬁed
26 single amino acid changes that cause a defect of both
export and binding to counter receptors. When wild-type
galectin-1 was analyzed in CHO clone 13 cells, a mutant
cell line incapable of expressing functional galectin-1
counter receptors, secretion was blocked. Intriguingly, we
G
 
also ﬁnd that a distant relative of galectin-1, the fungal
lectin CGL-2, is a substrate for nonclassical export from
Chinese hamster ovary (CHO) cells. Alike mammalian
galectin-1, a CGL-2 mutant defective in 
 
 
 
-galactoside
binding, does not get exported from CHO cells. We con-
clude that the 
 
 
 
-galactoside binding site represents the
primary targeting motif of galectins deﬁning a galectin
export machinery that makes use of 
 
 
 
-galactoside–con-
taining surface molecules as export receptors for intracel-
lular galectin-1.
 
Introduction
 
Galectins are 
 
 
 
-galactoside–specific lectins being associated
with components of the extracellular matrix and counter re-
ceptors on the cell surface of mammalian cells (Liu and
Rabinovich, 2005). Provided they contain 
 
 
 
-galactosides, both
glycoproteins and glycolipids can be clustered through interac-
tions with multivalent galectins, a key event in galectin signal
transmission to downstream targets (Brewer et al., 2002). Ga-
lectins have been implicated in a wide range of physiological
processes such as apoptosis, tumor progression, inflammation,
cell adhesion, and others (Perillo et al., 1998; Rabinovich et al.,
2002; Liu and Rabinovich, 2005). For example, galectin-1
(Gal-1) is secreted in large amounts from tumor cells, a process
that promotes immune suppression by inducing apoptosis of
activated T cells (Perillo et al., 1995; He and Baum, 2004).
However, galectins do not contain NH
 
2
 
-terminal signal pep-
tides for efficient and quantitative secretion but rather appear to
be tightly balanced between intra- and extracellular popula-
tions (Hughes, 1999; Nickel, 2003). In this regard, galec-
tins  belong to a heterogeneous group of secretory proteins
whose export mechanism does not depend on the classical ER/
Golgi apparatus–dependent secretory pathway (Hughes, 1999;
Nickel, 2003). Even though it has been known for more than 15
yr that Gal-1 export is mediated by an unconventional secre-
tory mechanism (Cooper and Barondes, 1990; Muesch et al.,
1990), the molecular machinery involved has remained elusive.
However, based on various experimental systems, evidence is
accumulating that Gal-1 export is mediated by direct transloca-
tion from the cytoplasm across the plasma membrane into the
extracellular space (Schäfer et al., 2004; Nickel, 2005).
So far, it has been assumed that galectins do not interact
with their counter receptors until they have been released into
the extracellular space. In the current study, we provide direct
evidence that these interactions are an integral part of the export
mechanism itself. We report that both Gal-1 mutants deficient in
 
 
 
-galactoside binding and mutant cell lines deficient in the bio-
genesis of galectin counter receptors are defective with regard to
Gal-1 secretion. These data are further emphasized by the find-
ing that CGL-2, a distant relative from the multicellular fungus
 
Coprinopsis cinerea
 
 with only limited similarity to mammalian
galectin-1 at the level of both primary and quaternary structure
(Lobsanov et al., 1993; Walser et al., 2004) and, therefore, not
being expected to be recognized as an export substrate in mam-
malian cells, is found to be secreted from CHO cells. Alike
mammalian Gal-1, CGL-2 export from CHO cells is blocked
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under conditions that do not permit interactions with 
 
 
 
-galacto-
side–containing counter receptors. The combined data presented
in this study establish that the so far elusive targeting motif of
Gal-1 is primarily defined by its 
 
 
 
-galactoside–specific carbohy-
drate recognition domain. Our findings suggest that galectin
ligands such as 
 
 
 
-galactoside–containing glycolipids act as
cargo receptors. We hypothesize that galectin counter receptors
either act at an intracellular level in order to recruit cytoplasmic
galectins to the nonclassical export pathway or at an extracellu-
lar level by exerting a pulling force to promote directional trans-
port of galectins across the plasma membrane.
 
Results
 
Identification of Gal-1 mutants deficient 
in binding to 
 
 
 
-galactosides
 
To elucidate the export targeting motif we generated more than
100 single amino acid mutants of human Gal-1. The individual
mutants were selected in three different ways: (1) a random
mutagenesis using a low fidelity PCR; (2) targeted mutagenesis
of surface residues based on the crystal structure of galectin-1
(Lobsanov et al., 1993); and (3) targeted mutagenesis of residues
conserved between human Gal-1 and CGL-2 from 
 
C. cinerea
 
.
All mutants were stably expressed as GFP fusion proteins in
CHO cells using a doxycycline-dependent transactivator system
(Engling et al., 2002). All mutant galectin proteins were ana-
lyzed for their capability to interact with counter receptors
based on binding to both CHO cells (Fig. 1 A) and lactose cou-
pled to beads (Fig. 1 B). Using the wild-type forms of Gal-1
and CGL-2 as positive controls and GFP alone as a negative
control, we identified a total of 26 Gal-1 mutants as being de-
ficient for binding to 
 
 
 
-galactoside–containing counter recep-
tors (Table I), some of which have been reported previously to
be impaired in terms of binding to 
 
 
 
-galactosides (Hiraba-
yashi and Kasai, 1991; Scott and Zhang, 2002; Ford et al.,
2003; Lopez-Lucendo et al., 2004). All mutants were clearly
defective in binding to 
 
 
 
-galactosides as they did not signifi-
cantly differ from the GFP negative control in both assays
(Fig. 1, A and B, lane 3).
 
Gal-1 mutants deficient for binding to 
 
 
 
-galactosides are also deficient for 
export from CHO cells
 
In previous studies, we established both a cell surface biotin-
ylation assay and a FACS-based assay system designed to quan-
titatively assess secretion of Gal-1 and other unconventional
secretory proteins from CHO cells (Seelenmeyer et al., 2003;
Stegmayer et al., 2005). To quantitatively study export of Gal-1
mutants deficient in binding to 
 
 
 
-galactosides, we combined
Figure 1. Analysis of  -galactoside binding efficiency of various galectin–
GFP fusion proteins based on binding to CHO cells and binding to lactose
beads. In A, the various fusion proteins indicated were expressed in CHO
cells. Cell-free supernatants were prepared and normalized by GFP fluo-
rescence. The various supernatants were then incubated with CHO cells
for 1 h at 4 C to allow cell surface binding. After treatment with affinity-
purified anti-GFP antibodies and APC-conjugated secondary antibodies,
cell surface binding was quantified by flow cytometry. In B, detergent ly-
sates normalized by GFP fluorescence were incubated with lactose beads
for 1 h at 4 C. The nonbound fraction was separated and, after extensive
washing, bound material was eluted with SDS sample buffer. Input (lane
1; 5%), nonbound material (lane 2; 5%), and bound material (lane 3; 5%)
were analyzed by SDS-PAGE and Western blotting using affinity-purified
anti-GFP antibodies. For further details see Materials and methods.
 
Table I. 
 
Single amino acid changes in human Gal-1 that cause
 
 
 
-galactoside binding deficiency
Mutation Selection procedure/reference
 
N34A Random mutagenesis/conserved between Ga-1 and CGL-2
D38K Surface exposure
N41A Random mutagenesis/conserved between Ga-1 and CGL-2
L44A Conserved between Ga-1 and CGL-2
L44D Conserved between Ga-1 and CGL-2
L44S Conserved between Ga-1 and CGL-2
H45A Random mutagenesis/conserved between Ga-1 and CGL-2; 
Scott and Zhang, 2002
F46A Conserved between Ga-1 and CGL-2
R49A Conserved between Ga-1 and CGL-2; Scott and Zhang, 
2002; Ford et al., 2003
H53A Random mutagenesis/surface exposure; Lopez-Lucendo et 
al., 2004
H53E Random mutagenesis/surface exposure; Lopez-Lucendo et 
al., 2004
H53G Random mutagenesis/surface exposure; Lopez-Lucendo et 
al., 2004
G54A Conserved between Ga-1 and CGL-2
N57A Random mutagenesis
V60A Random mutagenesis
W69G Hirabayashi and Kasai, 1991
E72A Conserved between Ga-1 and CGL-2; Hirabayashi and 
Kasai, 1991
R74A Conserved between Ga-1 and CGL-2; Hirabayashi and 
Kasai, 1991
F80K Random mutagenesis/conserved between Ga-1 and CGL-2
F80S Random mutagenesis/conserved between Ga-1 and CGL-2
R112A Conserved between Ga-1 and CGL-2
Y120D Random mutagenesis/conserved between Ga-1 and CGL-2
F127D Random mutagenesis/conserved between Ga-1 and CGL-2
I129R Surface exposure
V132E Random mutagenesis/surface exposure
V132R Random mutagenesis/surface exposure
 
Based on the procedures and/or references shown in the right column, a total of
26 amino acid changes are listed that cause a complete block of binding to
 
 
 
-galactoside–containing glycolipids and glycoproteins. For details see text. 
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these assays with immunoprecipitation of Gal-1–GFP fusion
proteins from the medium of the expressing cells using affin-
ity-purified anti-GFP antibodies. As shown in Fig. 2 A, most of
the extracellular Gal-1–GFP population was found to be asso-
ciated with the cell surface of CHO cells (lane 2) with only a
minor portion being found in the medium (lane 3). As controls,
both GFP without Gal-1 tag (Fig. 2 F) and endogenous Gal-1
(Fig. 2 G) were compared with Gal-1–GFP. As expected, GFP
could not be detected on the cell surface (Fig. 2 F, lane 2) and
only small amounts were detectable in the medium (Fig. 2 F,
lane 3). By contrast, endogenous Gal-1 was found both on the
cell surface and in the medium of CHO cells (Fig. 2 G). The
overall efficiency of Gal-1 versus Gal-1–GFP secretion was
similar with 
 
 
 
10% of each reporter molecule being localized
to the extracellular space under steady-state conditions. These
data indicate that tagging of Gal-1 with GFP does not interfere
with its secretion. Consistent with the biochemical data, the
wild-type form of Gal-1–GFP was detected on the cell surface
using the FACS assay as shown in Fig. 3. As expected, mutant
forms of Gal-1–GFP such as W69G and E72A, which are de-
fective with regard to binding to 
 
 
 
-galactosides could not be
detected on the cell surface using both the biotinylation (Fig.
2, B and C, lane 2) and the FACS assay (Fig. 3). Strikingly,
however, Gal-1–GFP
 
W69G
 
 and Gal-1–GFP
 
E72A
 
 were also absent
from the medium suggesting that they are not secreted from
CHO cells (Fig. 2, B and C, lane 3). We then tested whether
these Gal-1 mutants are stable in conditioned medium derived
from CHO cells in order to analyze whether protein degrada-
tion causes their absence from the supernatants of Gal-1–
GFP
 
W69G
 
 and Gal-1–GFP
 
E72A
 
-expressing cells. As demon-
strated in Fig. 4, both the wild-type form of Gal-1–GFP (A)
and the 
 
 
 
-galactoside-binding mutants (B and C, respectively)
are not degraded when incubated in conditioned CHO medium
at 37
 
 
 
C for 48 h (compare lanes 2 and 4). Thus, the absence of
the reporters from both the cell surface and the medium of
Gal-1–GFP
 
W69G
 
– and Gal-1–GFP
 
E72A
 
–expressing CHO cells
demonstrates that they are no substrates for the Gal-1 export
machinery. Intriguingly, the combined phenotypes for Gal-1–
GFP
 
W69G
 
 and Gal-1–GFP
 
E72A
 
 shown in Figs. 2–4 were also
Figure 2. Biochemical analysis of export of various galectin–GFP fusion
proteins from CHO cells using cell surface biotinylation and immuno-
precipitation from cell culture supernatants. The fusion proteins indi-
cated were expressed in CHO cells for 48 h at 37 C (six-well plates;
70% confluency). The medium was removed and subjected to immuno-
precipitation using affinity-purified anti-GFP antibodies. Cell surfaces
were treated with a membrane-impermeable biotinylation reagent. Af-
ter detergent-mediated cell lysis biotinylated and nonbiotinylated pro-
teins were separated using streptavidin beads. Aliquots from the input
material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the
immunoprecipitate from the cell culture medium fraction (lane 3; 50%)
were analyzed by SDS-PAGE and Western blotting using affinity-puri-
fied anti-GFP antibodies. In G, affinity-purified anti–Gal-1 antibodies
were used to detect endogenous Gal-1. For further details see Materials
and methods.
Figure 3. Quantitative analysis of export of various
galectin–GFP fusion proteins from CHO cells using flow
cytometry. CHO cells were grown on six-well plates and
induced with doxycycline for 48 h at 37 C to express the
fusion proteins indicated. After removal of the medium,
cells were labeled with affinity-purified anti-GFP antibod-
ies while they were still attached to the culture dishes. Pri-
mary antibodies were labeled with APC-conjugated sec-
ondary antibodies followed by detachment of the cells
using PBS/EDTA. GFP (expression level; green) and
APC-derived fluorescence (cell surface; blue) were quanti-
fied by flow cytometry using a FACSCalibur system
(Becton Dickinson; n   4). For further details see Materials
and methods. 
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found for all other 
 
 
 
-galactoside–binding mutants of Gal-1
listed in Table I (unpublished data). These findings imply that
binding to 
 
 
 
-galactosides of Gal-1 is a prerequisite to enter the
export pathway.
 
CGL-2, a distant relative of Gal-1 from 
the multicellular fungus 
 
C. cinerea
 
, is 
exported from CHO cells depending on 
its ability to bind to 
 
 
 
-galactosides
 
To challenge the hypothesis that the binding capacity of Gal-1
to 
 
 
 
-galactosides is a requirement for its export we analyzed
whether the fungal galectin ortholog CGL-2 is a substrate for
the Gal-1 export pathway in mammalian cells. Because homol-
ogies between Gal-1 and CGL-2 are extremely weak at the
level of both the primary and the quaternary structure (Lob-
sanov et al., 1993; Walser et al., 2004) and, in addition to the
typical galectin fold, efficient binding to 
 
 
 
-galactosides is a
common denominator of Gal-1 and CGL-2, we analyzed
whether CGL-2 is an export substrate in CHO cells. In both cell
surface biotinylation (Fig. 2 D) and flow cytometry (Fig. 3) ex-
periments, a CGL-2–GFP fusion protein was indeed found to
be an export substrate with similar efficiency as compared with
Gal-1. Intriguingly, a single-site mutation in a tryptophan resi-
due (W72G; analogous to W69G in Gal-1) essential for 
 
 
 
-galac-
toside binding (Walser et al., 2004; and Fig. 1, A and B) results
in a complete export block from CHO cells of CGL-2–GFP
(Fig. 2 E and Fig. 3). These data are consistent with the idea
Figure 4. Stability of galectin–GFP fusion proteins in conditioned media
derived from CHO cells. The fusion proteins indicated were expressed in
CHO cells for 48 h at 37 C (six-well plates; 70% confluency). From each
cell line, a cell-free supernatant was prepared. Normalized amounts (GFP
fluorescence) were incubated in conditioned medium derived from CHO
cells for the times indicated followed by immunoprecipitation (lanes 2–4)
using affinity-purified anti-GFP antibodies. The samples were analyzed by
SDS-PAGE and Western blotting using antibodies directed against GFP.
Lane 1, input (no IP, 10%); lane 2, no incubation (IP, 10%); lane 3, incu-
bation for 48 h at 4 C (IP, 10%); lane 4, incubation for 48 h at 37 C
(IP, 10%). For further details see Materials and methods.
Figure 5. Comparative analysis of export of galectin–GFP fusion proteins from CHO wild-type and CHO clone 13 cells using cell surface biotinylation and
immunoprecipitation from cell culture supernatants. The fusion proteins indicated were expressed in both CHO wild-type (A–F) and CHO clone 13 cells
(G–L) for 48 h at 37 C (six-well plates; 70% confluency). The medium was removed and subjected to immunoprecipitation using affinity-purified anti-GFP
antibodies. Cell surfaces were treated with a membrane-impermeable biotinylation reagent. After detergent-mediated cell lysis, biotinylated and non-
biotinylated proteins were separated using streptavidin beads. Aliquots from the input material (lane 1; 0.25%), the biotinylated fraction (lane 2; 25%)
and the immunoprecipitate from the cell culture medium fraction (lane 3; 25%) were analyzed by SDS-PAGE and Western blotting using affinity-purified
anti-GFP antibodies. For further details see Materials and methods. 
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that the 
 
 
 
-galactoside binding site is the primary export target-
ing motif of galectins and that interactions of galectins with
their counter receptors are essential for export.
 
Wild-type forms of both Gal-1 and CGL-2 
fail to be exported from CHO cells lacking 
functional counter receptors for galectins
 
To conclusively address the question whether counter recep-
tors play a direct role in the export mechanism of galectins, we
generated cell lines expressing various forms of Gal-1– and
CGL-2–GFP fusion proteins based on a CHO mutant termed
clone 13 (Briles et al., 1977; Deutscher and Hirschberg, 1986).
In this mutant cell line, the Golgi apparatus–resident trans-
porter for UDP-galactose is defective and hence, these cells
do not produce galectin counter receptors as galactosyltrans-
ferases in the Golgi lumen do not receive activated galactose
residues as substrates (Deutscher and Hirschberg, 1986). As a
result, both glycoproteins and glycolipids derived from clone
13 cells do not contain 
 
 
 
-galactosides in their sugar moieties
and, therefore, do not bind galectins on their cell surface (un-
published data).
As demonstrated in the cell surface biotinylation experi-
ments shown in Fig. 5, both Gal-1–GFP (A, lanes 2 and 3)
and CGL-2–GFP (D, lanes 11 and 12) are efficiently exported
from CHO wild-type cells (combined signals for cell surface
and medium fractions). By contrast, when expressed in CHO
clone 13 cells, the wild-type forms of Gal-1– and CGL-2–
GFP fusion proteins fail to get access to the extracellular
space as the combined signals for cell surface and medium
fractions (Fig. 5 G [lanes 2 and 3] and J [lanes 11 and 12], re-
spectively) do not differ significantly from the negative con-
trol (GFP; Fig. 5, G, F, and L [lanes 17 and 18]) and are
largely reduced as compared with those observed in CHO
wild-type cells (A and D, respectively). As expected, export
of 
 
 
 
-galactoside binding-deficient mutants (as exemplified by
W69G and E72A for Gal-1 as well as W72G for CGL-2) is
not only blocked in CHO wild-type cells (Fig. 2, B, C, and E;
Fig. 5, B, C, and E) but also in CHO clone 13 cells (Fig. 5, H,
I and K, respectively).
In Fig. 6, export from both CHO wild-type and CHO
clone 13 cells of the various galectin–GFP fusion proteins (as
measured by cell surface biotinylation and immunoprecipita-
tion from the cell culture supernatants) was quantified using
fluorescent secondary antibodies combined with a LI-COR
Odyssey imaging system. For each fusion protein, the com-
bined signals derived from cell surface biotinylation and ma-
terial from the cell culture supernatant were expressed as a
percentage of the overall expression level of a given fusion
protein. To compare export of the various fusion proteins, se-
cretion of Gal-1–GFP from CHO wild-type cells was set to
100%. As demonstrated in Fig. 6, the wild-type forms of both
Gal-1–GFP and CGL-2–GFP are secreted from CHO wild-
type cells, however, export is largely reduced when Gal-1–
GFP and CGL-2–GFP are expressed in CHO clone 13 cells.
The various mutant forms of Gal-1 and CGL-2 are neither ex-
ported from CHO wild-type nor from CHO clone 13 cells to a
significant extent.
 
Subcellular distribution of Gal-1–GFP and 
CGL2–GFP reporter molecules in CHO 
wild-type and CHO clone 13 cells
 
To compare the subcellular distribution of Gal-1 and CGL-2 mu-
tant forms with the corresponding wild-type proteins, we ana-
lyzed the cell lines described above by confocal microscopy
(Fig. 7). When living CHO wild-type cells were imaged, all re-
porters were found in the cytoplasm as well as to some extent in
the nucleus (Fig. 7, first column). When CHO wild-type and
CHO clone 13 (unpublished data) were compared, no differences
in live cell imaging could be observed for any of the reporter
molecules being analyzed. In general, a similar picture was ob-
Figure 6. Quantitation of export of galectin–GFP fusion proteins from CHO
wild-type and CHO clone 13 cells using cell surface biotinylation and
immunoprecipitation from cell culture supernatants. The fusion proteins
indicated were expressed in both CHO wild-type and CHO clone 13 cells
for 48 h at 37°C (six-well plates; 70% confluency). The medium was re-
moved and subjected to immunoprecipitation using affinity-purified anti-
GFP antibodies. Cell surfaces were treated with a membrane-impermeable
biotinylation reagent. After detergent-mediated cell lysis, biotinylated and
nonbiotinylated proteins were separated employing streptavidin beads.
Aliquots from the input material (0.25%), the biotinylated fraction (25%)
and the immunoprecipitate from the cell culture medium fraction (25%)
were analyzed by SDS-PAGE and Western blotting using affinity-purified
anti-GFP antibodies. Primary antibodies were detected with Alexa 680–
coupled anti–rabbit secondary antibodies. Signals for galectin–GFP fusion
proteins and GFP were quantified using a Odyssey imaging system (LI-COR
Biotechnology). The combined signals for the cell medium and the mate-
rial associated with the cell surface were calculated as a percentage of
the total amount of galectin–GFP fusion protein expressed in each case.
These data were corrected for unspecific release as monitored by GFP
present in the medium of the cells. The extracellular population of Gal-1–
GFP secreted from CHO wild-type cells was set to 100%. For further details
see Materials and methods. 
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served after fixation both for CHO wild-type and CHO clone 13
cells (Fig. 7, second and fourth column, respectively), however,
in some cases aggregates or particulate structures were observed
that apparently represent fixation artifacts. Consistent with the
FACS experiments shown in Fig. 3, cell surface staining of all
cell lines using affinity-purified anti-GFP antibodies revealed an
extracellular population in CHO wild-type cells only for the
wild-type forms of Gal-1–GFP and CGL2–GFP (Fig. 7, third
column). In CHO clone 13 cells, cell surface staining could not
be detected for any of the reporter molecules including the wild-
type forms of Gal-1 and CGL-2 (Fig. 7, fifth column).
 
Discussion
 
Galectins are extracellular modulators of a broad variety of
biomedically relevant cellular processes such as tumor progres-
sion and apoptosis (Liu and Rabinovich, 2005). For example,
galectin-1 is overproduced and secreted in large amounts from
tumor cells, a strategy of immune suppression by inducing
apoptosis of activated T cells (Perillo et al., 1995). However,
the export mechanism does not rely on the classical secretory
pathway as galectins neither contain signal peptides nor is the
efficiency of galectin export affected by brefeldin A (Hughes,
1999), a drug that blocks ER/Golgi apparatus–dependent secre-
tory transport (Misumi et al., 1986; Lippincott-Schwartz et al.,
1989; Orci et al., 1991). Galectins have therefore been termed
unconventional secretory proteins, however, the molecular ma-
chinery mediating galectin export from mammalian cells has
remained elusive (Hughes, 1999; Nickel, 2003).
In this study we identify galectin counter receptors (i.e.,
 
 
 
-galactoside–containing cell surface glyolipids and/or glyco-
proteins) as essential components of the overall process of Gal-1
secretion. Based on an unbiased screen, we have identified 26
single-site mutations in Gal-1 that cause both binding defi-
ciency to counter receptors and export deficiency. In fact, we
could not identify a single Gal-1 
 
 
 
-galactoside binding mutant
that retained export competence. To put this finding one step
further we analyzed Gal-1 secretion in a somatic CHO mutant
cell line defective in a Golgi apparatus–resident transporter that
is required for translocation of activated galactose from the cy-
toplasm into the lumen of the Golgi apparatus, a process essen-
tial for the generation of 
 
 
 
-galactoside–containing glyolipids
and glycoproteins (Deutscher and Hirschberg, 1986). Intrigu-
ingly, we found that wild-type Gal-1 fails to get exported from
this mutant cell line demonstrating that indeed secretion of
Gal-1 from mammalian cells strictly depends on functional in-
teractions between Gal-1 and its counter receptors. These data
are emphasized by our findings on CGL-2, a distant relative of
Figure 7. Subcellular distribution of Gal-1–GFP and
CGL-2–GFP reporter molecules in CHO wild-type and
CHO clone 13 cells as revealed by confocal microscopy.
First row, Gal-1–GFP; second row, Gal-1–GFPW69G; third
row, Gal-1–GFPE72A; forth row, CGL-2–GFP; fifth row,
CGL-2–GFPW72G; sixth row, GFP. First column, GFP live
imaging; second column, GFP imaging of fixed CHO
wild-type cells; third column, cell surface staining of fixed
CHO wild-type cells using affinity-purified anti-GFP anti-
bodies; fourth column, GFP imaging of fixed CHO clone
13 cells; fifth column, cell surface staining of fixed CHO
clone 13 cells using affinity-purified anti-GFP antibodies. 
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Gal-1 from the multicellular fungus 
 
C. cinerea
 
. Even though
similarities between CGL-2 and human Gal-1 are very weak at
both the level of the primary and the quaternary structure (Lob-
sanov et al., 1993; Walser et al., 2004), CGL-2 is recognized by
mammalian cells as an export substrate. Strikingly, a single-
site mutation (W72G) that is known to cause CGL-2 binding
deficiency to 
 
 
 
-galactosides (Walser et al., 2004), results in a
block of export from CHO cells of CGL-2, again consistent
with our finding that functional interactions with counter re-
ceptors are essential for the overall export process.
Regarding the molecular mechanism of Gal-1 export
from mammalian cells, there are two possible scenarios that
would be consistent with the data presented in this study. On
the one hand, galectin counter receptors on the cell surface
might be part of a molecular trap through which secreted Gal-1
molecules would be removed from an equilibrium between an
intracellular and an extracellular pool of Gal-1. In principle, the
extracellular galectin trap could be necessary for sustained Gal-1
export of the cytoplasmic pool. However, in the absence of
functional interactions between Gal-1 and its counter receptors,
Gal-1 export is apparently fully blocked (Fig. 2). Therefore, the
trapping mechanism does not satisfactorily explain our obser-
vations as Gal-1 transport should be observable at least to some
extent until a certain equilibrium between intra- and extracellu-
lar pools is reached. Therefore, in a variation of this model,
 
 
 
-galactoside–containing cell surface molecules might be
tightly coupled to the translocation machinery. In this way, counter
receptors might function by exerting a pulling force at the ex-
tracellular side of the putative translocation pore required for
directional transport of galectin-1 across the plasma membrane.
An alternative explanation of our results would be that
galectin counter receptors act as export receptors for Gal-1.
It is indeed tempting to speculate that Gal-1 interactions with
counter receptors are not restricted to the extracellular space
but rather already occur at the cytoplasmic side of the plasma
membrane. This assumption does, of course, not comply with
the established view, namely that for example glycolipids are
exclusively localized to the extracellular leaflet of the plasma
membrane with the glycan moieties being exposed to the ex-
tracellular space. However, it appears possible that a limited
number of, for example, 
 
 
 
-galactoside–containing glycolip-
ids gets translocated to the inner leaflet of the plasma mem-
brane catalyzed by a plasma membrane-resident flippase.
This subpopulation probably would not be detectable under
steady-state conditions. In this model, retrotranslocation of
counter receptors occupied by Gal-1 would mediate export to
the extracellular space.
Although both models are certainly speculative at this
point, they are consistent with several observations that have
been made previously. First, Gal-1 membrane translocation
has been reported to occur at the level of the plasma mem-
brane (Cooper and Barondes, 1990; Mehul and Hughes, 1997;
Hughes, 1999; Nickel, 2003; Schäfer et al., 2004). Second,
Huet and colleagues recently reported pharmacological evidence
that galectin-4 secretion is impaired in epithelial cells after treat-
ment with 1-benzyl-2-acetamido-2-deoxy-
 
 
 
-
 
D
 
-galactopyrano-
side, an inhibitor of glycosylation (Delacour et al., 2005).
Third, it has been reported that membrane translocation of both
FGF-2 and Gal-1 occurs in a folded state (Backhaus et al.,
2004). In the context of the current study, this finding is of par-
ticular interest as both models described above can only be true
if the 
 
 
 
-galactoside binding site of Gal-1 remains functional
during membrane translocation. In this regard, the putative
translocation machinery might be functionally related to the
bacterial twin-arginine translocation system through which
proteins are secreted in a fully folded state (Robinson and Bol-
huis, 2004; Nickel, 2005).
The findings presented in this study also provide a poten-
tial explanation for the apparent nonexistence of a linear target-
ing motif in Gal-1. Our data conclusively point to a direct role
of counter receptors as export adaptors and the 
 
 
 
-galactoside
binding motif of Gal-1 as the primary targeting element. In this
context, it is interesting to note that secretion from 
 
Saccharo-
myces cerevisiae
 
 of both rat galectin-1 and 
 
C. cinerea
 
 CGL-2
has been reported (Cleves et al., 1996; Boulianne et al., 2000).
This is because this organism does not contain endogenous
galectins and the existence of glycolipids and glycoproteins
containing 
 
 
 
-galactosides has not been clarified. It, therefore,
remains to be investigated whether secretion of galectins from
 
S. cerevisiae
 
 occurs by a molecular mechanism similar to that
of mammalian cells. Finally, it is of note that the secretory
mechanism being postulated in this study provides a functional
basis for quality control in the overall process of Gal-1 secre-
tion. As the 
 
 
 
-galactoside binding motif of Gal-1 is shown to
be the primary targeting element for secretion, quality control
is in place since only properly folded Gal-1 will be recognized
by the export machinery (Nickel, 2005).
 
Materials and methods
 
Antibodies
 
For flow cytometry analyses, immunoprecipitation experiments, and
Western blot detection of galectin–GFP fusion proteins affinity-purified
anti-GFP antibodies were used (Engling et al., 2002). Secondary anti-
bodies used for flow cytometry (allophycocyanin [APC]–conjugated anti–
rabbit antibodies) were from Invitrogen, HRP-coupled secondary antibod-
ies used for Western blot detection (ECL) of immunoprecipitates were
from Sigma-Aldrich (clone RG-16). Alexa 680–coupled anti–rabbit anti-
bodies used for quantitative analyses of antigens processed by Western
blotting (Fig. 6; Odyssey system; LI-COR Biotechnology) were purchased
from Invitrogen.
 
Generation of stable cell lines expressing both wild-type and mutant forms 
of galectin–GFP fusion proteins in a doxycycline-dependent manner
 
Mutant forms of Gal-1 and CGL-2 were generated by PCR-based site-
directed mutagenesis and cloned as GFP fusion constructs into the retrovi-
ral vector pREV-TRE2. CHO cell lines expressing the various fusion pro-
teins in a doxycycline-dependent manner were generated as described
previously (Engling et al., 2002; Seelenmeyer et al., 2003).
 
Quantitative analysis of galectin binding to cell surfaces using flow 
cytometry
 
Both wild-type and mutant forms of Gal-1–GFP and CGL-2–GFP fusion pro-
teins were expressed in CHO cells by incubating the cells in the presence
of doxycycline (1 
 
 
 
g/ml) for 48 h at 37
 
 
 
C. Cell-free supernatants were
prepared by homogenization combining freeze–thaw cycles with sonica-
tion. Membranes were removed in two steps by centrifugation at 1,000
 
g
 
av (10 min at 4 C) and 100,000 gav (1 h at 4 C). The resulting superna-
tants were analyzed for the amounts of fusion protein based on GFP fluo-
rescence as measured with a fluorescence plate reader (SpectraMax
Gemini XS; Molecular Devices Corp.). Normalized amounts of cell-free
supernatants (150 GFP units corresponding to  1.5  g GFP) were thenJCB • VOLUME 171 • NUMBER 2 • 2005 380
incubated with CHO cells not expressing galectin–GFP fusion proteins
(CHOMCAT-TAM2; Engling et al., 2002) for 1 h at 4 C to allow cell surface
binding. After treatment with affinity-purified anti-GFP antibodies and
APC-conjugated secondary antibodies, cell surface binding was quanti-
fied by flow cytometry as described before (Engling et al., 2002; Seelen-
meyer et al., 2003).
Biochemical analysis of galectin binding to counter receptors using lactose 
beads
Both wild-type and mutant forms of Gal-1–GFP and CGL-2–GFP fusion pro-
teins were expressed in CHO cells by incubating the cells in the presence
of doxycycline (1  g/ml) for 48 h at 37 C. After detachment of cells from
the culture dishes using PBS/EDTA, cells were sedimented and solubilized
in PBS/TX-100. Normalized amounts of the detergent lysates (50 GFP
units corresponding to  0.5  g GFP; SpectraMax Gemini XS; Molecular
Devices Corp.) were then incubated with lactose beads (Sigma-Aldrich)
for 1 h at 4 C. After extensive washing in TX-100–containing buffer,
bound material was eluted using SDS sample buffer. Both the flow-through
fraction and the SDS eluates were analyzed by SDS-PAGE and Western
blotting using anti-GFP antibodies as described in the legend of Fig. 1.
Biochemical analysis of galectin export from CHO cells using cell surface 
biotinylation and immunoprecipitation from cell culture supernatants
Galectin–GFP fusion proteins were expressed in the corresponding CHO
cell lines by incubation in the presence of doxycycline (1  g/ml) for 48 h at
37 C (six-well plates; 70% confluency). The medium was removed and the
cells washed once with PBS. Medium and PBS wash buffer were combined
and subjected to immunoprecipitation using affinity-purified anti-GFP an-
tibodies. To analyze secretion of endogenous Gal-1, affinity-purified
anti–Gal-1 antibodies (Seelenmeyer et al., 2003) were used for immuno-
precipitation experiments. Cell surfaces were treated with a membrane-
impermeable biotinylation reagent (EZ-Link Sulfo-NHS-SS-Biotin; Pierce
Chemical Co.). After detergent-mediated cell lysis, the cells were scraped off
the culture plates, insoluble material was then removed by low speed centri-
fugation. Biotinylated and nonbiotinylated proteins were separated using
streptavidin beads (UltraLink immobilized streptavidin; Pierce Chemical
Co.). Material bound to streptavidin beads was eluted with SDS sample
buffer. Samples from the input material, the nonbound fraction and the
streptavidin-bound fraction were analyzed by SDS-PAGE and Western blot-
ting as indicated in the legends to Figs. 2 and 5. For the biotinylation and
immunoprecipitation experiments depicted in Fig. 6, secondary antibodies
coupled to a fluorophor (Alexa 680) were used to allow quantitation of the
signal using a Odyssey imaging system (LI-COR Biotechnology).
Quantitative analysis of galectin export from CHO cells using flow 
cytometry
Galectin–GFP fusion proteins as well as GFP were expressed in the cor-
responding CHO cell lines by incubation in the presence of doxycycline
(1  g/ml) for 48 h at 37 C (six-well plates; 70% confluency). The medium
was removed and the cells washed once with PBS. Both primary (anti-GFP;
1 h) and secondary (APC-conjugated anti–rabbit; 30 min) antibody label-
ing was conducted at 4 C with the cells being attached to the culture
plates. The cells were then detached from the culture plates using cell dis-
sociation buffer (Life Technologies). Before the flow cytometry analysis,
propidium iodide (1  g/ml) was added in order to detect damaged cells.
GFP (expression level)- and APC-derived fluorescence (cell surface popula-
tion) were analyzed using a FACSCalibur flow cytometer (Becton Dickin-
son). Background fluorescence was determined by measuring CHOMACT-TAM2
cells (Engling et al., 2002), which were treated with both primary and sec-
ondary APC-conjugated secondary antibodies. GFP- and APC-derived
fluorescence were measured simultaneously without compensation.
Stability analysis of both wild-type and mutant forms of galectin–GFP 
fusion proteins in conditioned media derived from CHO cells
Cell-free supernatants of both wild-type and mutant forms of Gal-1–GFP and
CGL-2–GFP fusion proteins as well as GFP as a control were obtained as
described above. Normalized amounts (50 GFP units corresponding to
 0.5  g GFP; SpectraMax Gemini XS; Molecular Devices Corp.) were
then diluted 1:10 in conditioned medium derived from CHO cells. Samples
were then either directly subjected to immunoprecipitation using anti-GFP
antibodies (Fig. 4, lane 2), incubated for 48 h at 4 C followed by immuno-
precipitation (Fig. 4, lane 3) or incubated for 48 h at 37 C followed by im-
munoprecipitation (Fig. 4, lane 4). In each case, bound material was eluted
with SDS sample buffer. The samples were then analyzed by SDS-PAGE
and Western blotting using anti-GFP antibodies and anti–rabbit secondary
antibodies (clone RG-16; see above) coupled to HRP (ECL detection).
Confocal microscopy
CHO cells transduced with the reporter constructs indicated were grown
on glass coverslips for 36 h at 37 C in the presence of 1  g/ml doxycy-
cline (70% confluency). The cells were then either processed for live imag-
ing or subjected to paraformaldehyde fixation (3% wt/vol, 20 min at 4 C)
without permeabilization followed by antibody processing as indicated.
Alexa546-coupled secondary antibodies were used for cell surface stain-
ing experiments. The specimens were mounted in Fluoromount G (South-
ern Biotechnology Associates, Inc.) and viewed with a confocal micro-
scope (LSM 510; Carl Zeiss MicroImaging, Inc.).
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